Creative Touch Permanent Makeup and Aesthetics

GIP is a 42- amino acid peptide hormone secreted from enteroendocrine K cells of the duodenum and jejunum in response to nutrient ingestion, particularly fat and carbohydrate. It is the body’s principal incretin, accounting for 60–80% of the postprandial insulin response – the amplification of glucose-stimulated insulin secretion that occurs when nutrients arrive via the gut rather than intravenously. Beyond the pancreas, GIP acts directly on adipose tissue to upregulate lipoprotein lipase (LPL), promoting clearance of circulating triglycerides into adipocyte storage in the postprandial state. This adipose action – absent from GLP-1 – is part of what makes tirzepatide (a dual GIP/ GLP-1 receptor agonist) mechanistically distinct from and clinically superior to semaglutide: in the SURMOUNT-5 randomised trial, tirzepatide produced 20.2% mean weight loss at 72 weeks versus 13.7% with semaglutide. GIP’s biology in the context of obesity is complicated by a pharmacological paradox: both GIPR agonism and GIPR antagonism improve metabolic outcomes – a finding with significant and still unresolved implications for understanding why GIP receptor engagement at any extreme appears metabolically beneficial.

GIP’s full name has changed twice, and the history is instructive. It was originally called gastric inhibitory polypeptide for its weak ability to inhibit gastric acid secretion. When it was found to be a potent insulin secretagogue, the preferred name shifted to glucose-dependent insulinotropic polypeptide – same acronym, different identity. The glucose-dependent qualifier matters: GIP stimulates insulin secretion only when blood glucose is elevated, not at fasting levels. This glucose-dependency built into the mechanism means GIP does not cause hypoglycaemia on its own – a pharmacologically desirable property that has shaped how its receptor agonists are engineered. ^[4]

Secretion, Structure, and the Incretin Effect

GIP is synthesised and released from K cells, a population of enteroendocrine cells concentrated in the duodenum and proximal jejunum – the first intestinal segments to receive nutrient-rich gastric contents. Fat and carbohydrate are the primary secretagogues; protein is a weaker stimulus. GIP is rapidly inactivated by the enzyme DPP-4 (dipeptidyl peptidase-4), which cleaves its N-terminal dipeptide to produce GIP(3–42), a metabolite that may act as a weak GIPR antagonist. ^[8] The biological half-life of intact GIP is consequently short – approximately 5 minutes in circulation – meaning the postprandial GIP signal is sharp and meal-coupled rather than sustained.

The incretin effect – the observation that oral glucose produces substantially more insulin secretion than the same glucose load delivered intravenously – was the experimental phenomenon that identified both incretins. GIP and GLP-1 together account for this amplification; GIP is the larger contributor, responsible for 60–80% of the postprandial insulin response under normal conditions. ^[8] At the β cell, GIP binds GIPR, a Gs-coupled receptor, activating adenylyl cyclase, raising intracellular cAMP, and potentiating glucose-stimulated insulin exocytosis. It also promotes β-cell survival by inhibiting apoptosis – a shared property with GLP-1 that has been studied in the context of preserving β-cell mass in type 2 diabetes. ^[6]

The Adipose Action: Where GIP Diverges from GLP-1

The critical mechanistic distinction between the two incretins is what happens in adipose tissue. GLP-1 has no meaningful direct adipose action. GIP does – and it is the primary reason GIP has been characterised as a “feast hormone” operating beyond the pancreas. In the presence of insulin (which rises alongside GIP after every meal), GIP directly activates LPL in human adipocytes through a PI3K/PKB/ AMPK-dependent CREB/TORC2 pathway, increasing LPL gene expression and enzyme activity. ^[2] LPL is the enzyme that hydrolyses triglycerides in circulating lipoproteins, releasing fatty acids for uptake into adipocytes. GIP-driven LPL upregulation therefore accelerates the clearance of postprandial triglycerides from circulation into fat storage. ^[6]

Physiologically, this makes sense: GIP is released by the same meal that is delivering dietary fat into circulation, and its LPL-activating effect ensures that fat is efficiently deposited into adipose tissue alongside the glucose that insulin is directing to muscle and liver. GIP’s adipose action also suppresses AMPK within adipocytes – reducing fat oxidation at the cellular level in the postprandial window, reinforcing the storage orientation of the fed state. ^[6] In a lean metabolic context, this is appropriate and temporary. In the context of chronic overnutrition and repeated high-fat, high-carbohydrate meals, GIP’s adipose action becomes part of the mechanism by which the postprandial state consistently prioritises storage over oxidation.

The GIP Paradox in Obesity

GIP biology takes a counterintuitive turn in obesity, which matters for understanding tirzepatide’s mechanism and the science being done around it. Circulating GIP is elevated in obesity – obese individuals secrete more GIP in response to meals than lean individuals. ^[9] Yet the GIPR appears functionally desensitised in this state: the incretin effect (GIP-mediated insulin amplification) is markedly impaired in type 2 diabetes, despite GIP levels being normal or elevated. GIPR downregulation and receptor desensitisation under conditions of chronic stimulation appear to explain this.

More puzzling is what happens when GIPR is pharmacologically targeted in opposing directions: both GIPR agonism (tirzepatide) and GIPR antagonism (investigational compounds) improve metabolic outcomes and reduce adiposity in animal models and emerging human data. ^[5] One explanation proposed for this paradox is that chronic GIPR agonism produces sufficient receptor desensitisation that the downstream effect becomes functionally equivalent to antagonism over time – a form of pharmacological judo where sustained activation achieves the same end as blockade. The mechanistic resolution is not yet established. This is active research territory, and honest clinical communication about tirzepatide should acknowledge that the full mechanistic explanation for its GIPR contribution to weight loss remains under investigation.

GIP and Bone

A less discussed but clinically relevant action of GIP is in bone metabolism. GIP promotes bone formation; GLP-1 inhibits bone resorption. ^[6] The two incretins therefore approach skeletal health from complementary directions – one adding, one preventing subtraction. GIPR is expressed on osteoblasts, and GIP infusion increases markers of bone formation in human studies. This is relevant in the context of significant rapid weight loss from GLP-1 receptor agonists or tirzepatide, where modest reductions in bone mineral density (typically 1–2.6% at hip and spine sites) are a recognised consequence of the weight loss itself. ^{[1] [3]} GIP has well-documented anabolic effects on bone (promoting osteoblast survival and reducing osteoclast activity). Whether the GIP component of tirzepatide provides a meaningful relative bone-protective advantage over pure GLP-1 agonism remains under investigation; current clinical data show similar patterns of modest BMD loss driven primarily by the magnitude of weight reduction.